Our results suggest that different detection ranges for NAT should be defined in the diagnostic guidelines according to the level of severity of the COVID-19 epidemic in each location to improve the positive detection rate and conserve and rationally allocate medical resources. This evidence concerns the gene BRD2 and COVID-19.